Compare BILL & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | SRRK |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2019 | 2018 |
| Metric | BILL | SRRK |
|---|---|---|
| Price | $53.49 | $44.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $61.05 | $47.00 |
| AVG Volume (30 Days) | ★ 2.4M | 2.1M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,499,861,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $13.30 | $20,271.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.63 | N/A |
| 52 Week Low | $36.55 | $22.71 |
| 52 Week High | $100.19 | $46.98 |
| Indicator | BILL | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 69.88 |
| Support Level | $49.51 | $39.51 |
| Resistance Level | $50.26 | $43.94 |
| Average True Range (ATR) | 1.73 | 2.25 |
| MACD | 0.54 | 0.56 |
| Stochastic Oscillator | 92.62 | 91.11 |
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.